Viridian Therapeutics Inc
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develo… Read more
Viridian Therapeutics Inc (VRDN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.033x
Based on the latest financial reports, Viridian Therapeutics Inc (VRDN) has a cash flow conversion efficiency ratio of -0.033x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-23.75 Million) by net assets ($722.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Viridian Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Viridian Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Viridian Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Viridian Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hangzhou Great Star Industrial Co Ltd
SHE:002444
|
0.030x |
|
Western Union Co
NYSE:WU
|
0.281x |
|
Eutelsat Group
LSE:ETL
|
0.071x |
|
Pennon Group Plc
PINK:PEGRF
|
0.122x |
|
Olympic Circuit Technology Co Ltd
SHG:603920
|
0.048x |
|
First Hawaiian Inc
NASDAQ:FHB
|
0.021x |
|
Hyosung Heavy Industries Corp
KO:298040
|
-0.047x |
|
Walsin Lihwa Corp
TW:1605
|
0.021x |
Annual Cash Flow Conversion Efficiency for Viridian Therapeutics Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Viridian Therapeutics Inc from 2012 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $722.17 Million | $-276.39 Million | -0.383x | -10.65% |
| 2024-12-31 | $671.64 Million | $-232.32 Million | -0.346x | +16.98% |
| 2023-12-31 | $442.02 Million | $-184.17 Million | -0.417x | -75.41% |
| 2022-12-31 | $395.06 Million | $-93.84 Million | -0.238x | +18.31% |
| 2021-12-31 | $187.72 Million | $-54.58 Million | -0.291x | -17.20% |
| 2020-12-31 | $120.04 Million | $-29.78 Million | -0.248x | +89.16% |
| 2019-12-31 | $15.75 Million | $-36.06 Million | -2.289x | -337.75% |
| 2018-12-31 | $51.34 Million | $-26.84 Million | -0.523x | +28.52% |
| 2017-12-31 | $38.51 Million | $-28.17 Million | -0.731x | -103.30% |
| 2016-12-31 | $-326.00K | $-7.23 Million | 22.181x | +3447.41% |
| 2015-12-31 | $10.41 Million | $-6.90 Million | -0.663x | -79.39% |
| 2014-12-31 | $5.99 Million | $-2.21 Million | -0.369x | +35.90% |
| 2013-12-31 | $2.03 Million | $-1.17 Million | -0.576x | -298.50% |
| 2012-12-31 | $-21.44 Million | $-6.22 Million | 0.290x | -- |